103 related articles for article (PubMed ID: 3978648)
1. Disposition of mitoxantrone in cancer patients.
Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of mitoxantrone.
Ehninger G; Proksch B; Heinzel G; Woodward DL
Cancer Treat Rep; 1986 Dec; 70(12):1373-8. PubMed ID: 3791250
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
Lu K; Loo TL
Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Schilcher RB; Young JD; Leichman LP; Haas CD; Baker LH
Cancer Res; 1983 Aug; 43(8):3907-11. PubMed ID: 6683127
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of mitomycin C in humans.
den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
[TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
10. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and metabolism of mitoxantrone in man.
Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone in patients with acute leukemia in relapse.
Paciucci PA; Ohnuma T; Cuttner J; Silver RT; Holland JF
Cancer Res; 1983 Aug; 43(8):3919-22. PubMed ID: 6861154
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of mitoxantrone in cancer patients.
Savaraj N; Lu K; Manuel V; Loo TL
Cancer Chemother Pharmacol; 1982; 8(1):113-7. PubMed ID: 7094196
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
17. Elimination pathways of [14C]losoxantrone in four cancer patients.
Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
20. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
